DongKoo Bio & Pharma Co Ltd banner
D

DongKoo Bio & Pharma Co Ltd
KOSDAQ:006620

Watchlist Manager
DongKoo Bio & Pharma Co Ltd
KOSDAQ:006620
Watchlist
Price: 5 500 KRW 0.18%
Market Cap: ₩156.5B

Relative Value

The Relative Value of one DongKoo Bio & Pharma Co Ltd stock under the Base Case scenario is hidden KRW. Compared to the current market price of 5 500 KRW, DongKoo Bio & Pharma Co Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

DongKoo Bio & Pharma Co Ltd Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
DongKoo Bio & Pharma Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
DongKoo Bio & Pharma Co Ltd
KOSDAQ:006620
148.7B KRW 0.6 193.1 15.5 38.6
US
Eli Lilly and Co
NYSE:LLY
923.3B USD 14.2 44.7 30.2 32.2
US
Johnson & Johnson
NYSE:JNJ
582.8B USD 6.2 21.7 15.1 18.6
CH
Roche Holding AG
SIX:ROG
253.4B CHF 4.1 19.6 11.6 13.1
UK
AstraZeneca PLC
LSE:AZN
223.5B GBP 5.1 29.3 16.2 22.9
CH
Novartis AG
SIX:NOVN
231.8B CHF 5.3 21.4 13.2 17
US
Merck & Co Inc
NYSE:MRK
286.8B USD 4.4 15.7 9.8 11.9
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.6 10.8 8 9.4
US
Pfizer Inc
NYSE:PFE
152.7B USD 2.4 19.7 7.6 10.1
US
Bristol-Myers Squibb Co
NYSE:BMY
118.7B USD 2.5 16.8 7.1 8.8
P/E Multiple
Earnings Growth PEG
KR
D
DongKoo Bio & Pharma Co Ltd
KOSDAQ:006620
Average P/E: 39.3
193.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
44.7
32%
1.4
US
Johnson & Johnson
NYSE:JNJ
21.7
7%
3.1
CH
Roche Holding AG
SIX:ROG
19.6
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
29.3
26%
1.1
CH
Novartis AG
SIX:NOVN
21.4
14%
1.5
US
Merck & Co Inc
NYSE:MRK
15.7
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
1%
10.8
US
Pfizer Inc
NYSE:PFE
19.7
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.8
16%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
D
DongKoo Bio & Pharma Co Ltd
KOSDAQ:006620
Average EV/EBITDA: 43.6
15.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
30.2
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
15.1
2%
7.6
CH
Roche Holding AG
SIX:ROG
11.6
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
16.2
13%
1.2
CH
Novartis AG
SIX:NOVN
13.2
5%
2.6
US
Merck & Co Inc
NYSE:MRK
9.8
3%
3.3
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8
1%
8
US
Pfizer Inc
NYSE:PFE
7.6
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.1
-10%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett